Dianthus Therapeutics, Inc. is a New York-based clinical-stage biotechnology firm dedicated to innovating monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The company boasts a promising pipeline of proprietary drug candidates that address significant unmet medical needs and advance through critical clinical trials. With a specialization in precision medicine, Dianthus is strategically positioned for substantial breakthroughs, making it an attractive investment prospect for institutional investors interested in the evolving biopharmaceutical sector. Show more

Location: 7 TIMES SQUARE, NEW YORK, NY, UNITED STATES, 10036, New York, NY, 10036, USA | Website: https://dianthustx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.308B

52 Wk Range

$13.37 - $57.50

Previous Close

$53.36

Open

$53.36

Volume

2,827,517

Day Range

$52.80 - $57.50

Enterprise Value

1.905B

Cash

55.98M

Avg Qtr Burn

-30.56M

Insider Ownership

3.36%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Claseprubart (DNTH103) Details Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Generalized Myasthenia Gravis (gMG)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Multifocal Motor Neuropathy (MMN)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MGTA-145 + plerixafor Details Multiple myeloma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LBL-047 (DNTH212) (BDCA2/TACI Inhibitor) Details Systemic Lupus Erythematosus	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.